A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers

A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers

Conditions: Gynecologic Neoplasms; Epithelial Ovarian Cancer; Uterine Endometrial Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: Pembrolizumab
Sponsors: AA Secord; Merck Sharp & Dohme LLC
Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 22, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments